Bio-Rad Laboratories, Inc.Class A (BIO) is a publicly traded Healthcare sector company. As of November 4, 2026, BIO trades at $379.63 with a market cap of $10.02B and a P/E ratio of 46.18. BIO moved +1.17% today. Year to date, BIO is +17.76%; over the trailing twelve months it is +22.07%. Its 52-week range spans $211.43 to $396.23. Analyst consensus is buy with an average price target of $360.00. Rallies surfaces BIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bio-Rad Q3 EBIT margin -7.6%: Bio-Rad reported a Q3 EBIT margin of -7.6%, net income of $458.6 million, EPS of $17.02, sales of $656.4 million and gross margin of 50.1%.
| Metric | Value |
|---|---|
| Price | $379.63 |
| Market Cap | $10.02B |
| P/E Ratio | 46.18 |
| EPS | $8.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $396.23 |
| 52-Week Low | $211.43 |
| Volume | 232.94K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.59B |
| Net Income | $222.40M |
| Gross Margin | 51.90% |
2 analysts cover BIO: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $360.00.